Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs Manhattan Associates Inc (MANH) Price & Performance

DexCom, Inc.Trade
Manhattan Associates IncTrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs Manhattan Associates Inc — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Manhattan Associates Inc trades at $192.8 (market cap $11.38B). The key difference: DexCom, Inc. is far larger — about 3× Manhattan Associates Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Manhattan Associates Inc nearer its low. Which is the better fit depends on your goals.

DXCMMANH
Market Cap
$33.79B$11.38B
Sector
HealthTechnology
52-Week High
$89.53$220.19
52-Week Low
$54.84$120.88
Enterprise Value
$33.24B$11.25B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.

The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.

Manhattan Associates Inc

MANH is trading at $192.63, down 1.56% on the day, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company reported robust Q2 2026 earnings, beating EPS estimates with $1.39 versus $1.32 expected, driven by 26% cloud revenue growth. However, valuation ratios remain elevated with a P/E of 55.93 and P/B of 72.26, indicating high investor expectations. Recent news highlights an ongoing legal investigation into fiduciary duties by the Rosen Law Firm, creating a mixed sentiment backdrop.

The outlook for MANH is cautiously optimistic, with a consensus price target of $210.33 offering 9.2% upside potential. Key opportunities include sustained cloud growth and strong profitability metrics like a 96.38% ROE. Risks involve the high valuation, potential legal overhangs from the investigation, and any slowdown in enterprise software demand. Institutional analysts maintain an 80% buy rating, suggesting confidence in execution despite near-term headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM

About Manhattan Associates Inc

Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.

Read more on MANH